{
  "docId": "019de074-cfba-73af-96cf-2b33e6c699c9",
  "docSlug": "90ad9e76f71a7983fe14e2a7d36252ee",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 28,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines two distinct study arms involving AB-729, VTP-300, and Nivolumab, with a primary focus on safety and reactogenicity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-cfba-73af-96cf-2b33e6c699c9/18",
  "deckHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9",
  "deckJsonHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9.json",
  "deckAnchorHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.7,
        "x": 0.28,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Clinical trial timeline showing weeks 1-24, 26-48, and follow-up periods.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3a89d93-32d8-4803-9a59-e8035a025903",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "list",
      "text": "Primary objective: evaluate safety and reactogenicity of AB-729 followed by VTP-300 or placebo. At week 48 all participants who are eligible to discontinue NA therapy will be followed for 48-weeks. Expand the clinical trial to include an additional arm with nivolumab (Opdivo), and dose first patient in this arm in the first half of 2023. Full rights retained by the Companies of their respective product candidates and all costs split equally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c8a8a5e-a0f4-4a5c-907e-ee03c5bbed87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.04,
        "y": 0.575
      },
      "kind": "paragraph",
      "text": "POC Phase 2a clinical trial evaluating AB-729 in combination with Vaccitech's immunotherapeutic, VTP-300, and a NA. Preliminary data expected in 2H '23",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0eb5d63-84eb-4c8b-92b7-9018f13b8223",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.25,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "AB-729-202: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee30c49c-3a1f-4085-9d67-cc6877305eaf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "80460142-437a-4666-9077-72c75233209a",
      "evidence": "The timeline visualization of clinical trial phases.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 28,
      "from": 3,
      "beatId": "708d5cbd-cd14-4361-ab43-54fc6ba4b110",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Our Strategy, Broad Pipeline, AB-729 RNAi Therapeutic, and other solution-focused slides",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}